Zentalis Pharmaceuticals (ZNTL) Enterprise Value (2022 - 2025)
Zentalis Pharmaceuticals (ZNTL) has 4 years of Enterprise Value data on record, last reported at -$286.6 million in Q2 2025.
- For Q2 2025, Enterprise Value fell 675.21% year-over-year to -$286.6 million; the TTM value through Sep 2025 reached -$486.2 million, down 1076.68%, while the annual FY2024 figure was -$19.2 million, 95.78% up from the prior year.
- Enterprise Value reached -$286.6 million in Q2 2025 per ZNTL's latest filing, down from -$12.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$12.2 million in Q1 2025 and bottomed at -$454.8 million in Q4 2023.
- Average Enterprise Value over 4 years is -$105.2 million, with a median of -$41.8 million recorded in 2022.
- Peak YoY movement for Enterprise Value: tumbled 961.37% in 2023, then surged 95.78% in 2024.
- A 4-year view of Enterprise Value shows it stood at -$42.8 million in 2022, then crashed by 961.37% to -$454.8 million in 2023, then soared by 95.78% to -$19.2 million in 2024, then crashed by 1394.94% to -$286.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$286.6 million in Q2 2025, -$12.2 million in Q1 2025, and -$19.2 million in Q4 2024.